RELMADA THERAPEUTICS, INC. (RLMD) is a publicly traded company in the Unknown sector. Across all available filings, 9 corporate insiders have executed 214 transactions totaling $17.8M, demonstrating a bearish sentiment with -$8.6M in net insider flow. The most recent transaction on Dec 15, 2025 involved a purchase of 11,665 shares valued at $48.1K.
No significant insider buying has been recorded for RLMD in the recent period.
No significant insider selling has been recorded for RLMD in the recent period.
Based on recent SEC filings, insider sentiment for RLMD is bearish with an Insider Alignment Score of 26/100 and a net flow of -$8.6M. Insiders are reducing their positions, though this can be driven by factors unrelated to company outlook.
Insider trading at RELMADA THERAPEUTICS, INC. (RLMD) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 9 insiders are actively trading RLMD stock, having executed 214 transactions in the past 90 days. The most active insider is Paul Edward Kelly (Executive), who has made 49 transactions totaling $8.8M.
Get notified when executives and directors at RLMD file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Dec 15, 2025 | Shenouda Maged | Executive | Purchase | 11,665 | $4.12 | $48.1K | |
| Dec 15, 2025 | Traversa Sergio | Executive | Purchase | 27,500 | $4.12 | $113.3K | |
| Nov 5, 2025 | Edward Kelly Paul | Executive | Purchase | 90,000 | $2.20 | $198.0K | |
| Nov 5, 2025 | Shenouda Maged | Executive | Purchase | 500,000 | $2.20 | $1.1M | Large |
| Nov 5, 2025 | Traversa Sergio | Executive | Purchase | 272,500 | $2.20 | $599.5K | Large |
| Nov 5, 2025 | Ence Chuck | Executive | Purchase | 136,000 | $2.20 | $299.2K | |
| Aug 28, 2025 | Traversa Sergio | Executive | Purchase | 55,976 | $0.74 | $41.4K | |
| Aug 27, 2025 | Traversa Sergio | Executive | Purchase | 129,455 | $0.67 | $86.7K | |
| Aug 26, 2025 | Traversa Sergio | Executive | Purchase | 80,545 | $0.62 | $49.9K | |
| Sep 11, 2024 | Shenouda Maged | Executive | Purchase | 24,120 | $2.95 | $71.2K | |
| Sep 11, 2024 | Traversa Sergio | Executive | Purchase | 51,407 | $2.99 | $153.7K | |
| Sep 10, 2024 | Shenouda Maged | Executive | Purchase | 21,118 | $2.73 | $57.7K | |
| Sep 10, 2024 | Traversa Sergio | Executive | Purchase | 33,014 | $2.75 | $90.8K | |
| Sep 9, 2024 | Edward Kelly Paul | Executive | Purchase | 25,000 | $2.59 | $64.8K | |
| Sep 9, 2024 | Shenouda Maged | Executive | Purchase | 8,194 | $2.55 | $20.9K |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Sale(S) | 86 | $13.2M | 60.4% |
Purchase(P) | 79 | $4.6M | 20.9% |
Exercise(M) | 36 | $3.1M | 14.0% |
Payment(F) | 5 | $566.4K | 2.6% |
Exercise (Options)(X) | 2 | $307.5K | 1.4% |
Conversion(C) | 1 | $160.9K | 0.7% |
Gift(G) | 5 | $0 | 0.0% |
Insider selling pressure at RELMADA THERAPEUTICS, INC. has increased, with 9 insiders executing 214 transactions across all time. Total sales of $13.2M significantly outpace purchases of $4.6M, resulting in a net outflow of $8.6M. This selling activity appears largely discretionary, which may warrant closer attention from investors.